At 6 months, the win ratio favored the device over optimal medical therapy, in large part driven by improved quality of life.

Underdiagnosis and undertreatment likely drive the profound effects observed in certain populations, says Juan Granada.

The IRIS-MAIN registry results did show some differences in nonfatal outcomes like stroke, MI, and revascularization.

The postapproval study makes the case that Symplicity Spyral reduces BP across a wide swath of real-world populations.

SIRONA tested the sirolimus DCB against seven commercially available paclitaxel DCBs. The study randomized 482 patients (mean ...

Using previously obtained CT scans, operators were able to plan procedures ahead of time, with no ill effects on outcome.

The rates of TLF were considerably lower than the investigators expected, leading to questions about experience and selection ...

Immediate costs are higher for TAVI, but patients and the healthcare system benefit long-term from earlier intervention.

REMEDY-PILOT showed the safety and feasibility of using the device, but with no effects on perfusion or angina symptoms.

SAN DIEGO, CA—Patients treated with the Agent drug-coated balloon (DCB; Boston Scientific) have encouraging outcomes at 1 ...

SIMPLAAFY was a multicenter, open-label trial that included 1,857 patients (mean age 76 years; 43% women) with AF who underwent LAAO with the Watchman FLX Pro device (Boston Scientific) without ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...